NCT06402487

Propionic Acid in Multiple Sclerosis

Propionic Acid in Multiple Sclerosis - a Placebo-controlled Randomized Double-blinded Clinical Trial

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 101 (actual)
• Sponsor: Salzburger Landeskliniken · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to demonstrate the superiority of propionic acid over placebo as add on treatment in multiple sclerosis (MS).

Detailed description

This is a single-center, double-blinded, randomized trial. One hundred multiple sclerosis (MS) patients will be randomly assigned in a 2:1 ratio to receive either 100 mg of propionic acid or a placebo over a period of 90 days. Outcome measures will encompass NfL and GFAP levels, fatigue scores, quality of life assessments, and physical examinations. Additionally, subgroup analysis will involve the evaluation of MRI and MEG data.

Conditions

• Multiple Sclerosis

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Propionic acid 1000 mg capsule	Patients will be assigned to propionic acid or placebo as add on MS treatment.
DIETARY_SUPPLEMENT	Placebo	Patients will be assigned to propionic acid or placebo as add on MS treatment.

Timeline

• Start date: 2024-05-01
• Primary completion: 2024-09-15
• Completion: 2024-10-09
• First posted: 2024-05-07
• Last updated: 2024-10-15

Locations

1 site across 1 country: Austria